New drug combo tested in Tough-to-Treat skin cancer

NCT ID NCT04109456

Summary

This early-stage study tested a new drug called IN10018, both alone and in combination with other cancer drugs, in 51 adults with advanced melanoma that had spread. The main goal was to check the safety of these treatments and see how the body processes the drug. Researchers also looked for early signs that the treatments could help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

  • MD Anderson

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • St Vincent Hospital Sydney

    Sydney, New South Wales, Australia

  • Sylvester Comprehensive Cancer Center.

    Miami, Florida, 33136, United States

  • The Alfred Hospital

    Melbourne, Victoria, Australia

Conditions

Explore the condition pages connected to this study.